Fine Foods & Pharmaceuticals N.T.M. SpA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IT0005215329
EUR
9.84
0.2 (2.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Fine Foods & Pharmaceuticals N.T.M. SpA stock-summary
stock-summary
Fine Foods & Pharmaceuticals N.T.M. SpA
Pharmaceuticals & Biotechnology
Fine Foods & Pharmaceuticals NTM SpA, formerly Innova Italy 1 SpA, is an Italy-based pharmaceutical company. It is specialized in the manufacturing of pharmaceutical products for third parties. The Company manages three segments: Pharmaceuticals, Nutraceuticals and Medical Devices. The Pharmaceuticals segment includes powders and granules, tablets, coated tablets and hard gelatin capsules, packaged in sachets, blisters and bottles. The Nutraceuticals segment includes soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, coated tablets and hard gelatin capsules packaged in bags, sachets, sticks, jars, tablet bottles, blisters and strips. The Medical Devices segment includes tablets, capsules, powders, granules and cover the areas for gastrointestinal, oral and throat treatment and the weight management. Medical Devices marked CE (European Conformity) are available for licensing.
Company Coordinates stock-summary
Company Details
Via Berlino, 39, Zingonia , VERDELLINO None : 24040
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Marco Eigenmann
Chairman of the Board
Mr. Giorgio Ferrais
Chief Executive Officer, Director
Mr. Fulvio Conti
Director
Mr. Marco Costaguta
Director
Mr. Paolo Ferrario
Director
Mr. Federico Oriani
Director
Mr. Adriano Pala Ciurlo
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
66 Million
(Quarterly Results - Jun 2025)
Net Profit:
5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 214 Million ()

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.09

stock-summary
Return on Equity

9.09%

stock-summary
Price to Book

1.55